Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.57 |
| ▸ | HPGD | P15428 | 8/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140140 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL30411552 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL25339386 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL11845115 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL16377044 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29985618 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL15163923 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL4066614 | 0.78 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL17164131 | 0.77 | RECQL (0.67) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL18704182 | 0.77 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569645-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1569932-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | US | claimed |
| WO-2004055015-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| WO-2004054505-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10174019-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-07-26 | — | — | US | disclosed |
| WO-2017184999-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2004055015-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054505-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-4906288-A | Herbicidal pyridyl sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4723991-A | Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| EP-0125864-B1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-04-08 | — | — | EP | disclosed |
| EP-0125864-A1 | Herbicidal sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP2K2, MAP3K2 | KDM4E 1736/4885ALDH1A1 4315/4885HPGD 1207/4885 |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | KDM4E 59/4885ALDH1A1 1572/4885HPGD 1587/4885 |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | KDM4E 59/4885ALDH1A1 1572/4885HPGD 1587/4885 |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | MAP4K2, MAP3K20, MAPKAPK2 | KDM4E 1684/4885ALDH1A1 3796/4885HPGD 806/4885 |
| US-10174019-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | CYP3A5, PAICS, CYP4B1 | KDM4E 1189/4885ALDH1A1 594/4885HPGD 374/4885 |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | KDM4E 59/4885ALDH1A1 1572/4885HPGD 1587/4885 |
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | KDM4E 1189/4885ALDH1A1 594/4885HPGD 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.